AbbVie Inc. Files 8-K on Financial Operations

Ticker: ABBV · Form: 8-K · Filed: 2024-07-25T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, debt, disclosure

Related Tickers: ABBV

TL;DR

AbbVie dropped an 8-K on 7/25 detailing financial ops and senior notes.

AI Summary

On July 25, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior notes, such as the 0.750% Senior Notes due 2027 and 2.125% Senior Notes due 2028, indicating ongoing financial activities and debt management.

Why It Matters

This filing provides insight into AbbVie's current financial standing and debt structure, which is crucial for investors assessing the company's stability and future prospects.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by AbbVie Inc.?

The primary purpose of this 8-K filing is to report on AbbVie Inc.'s Results of Operations and Financial Condition, as well as to file Financial Statements and Exhibits.

What specific debt instruments are mentioned in the filing?

The filing mentions several senior notes, including the 0.750% Senior Notes due 2027, 2.125% Senior Notes due 2028, 2.625% Senior Notes Due 2028, 2.125% Senior Notes Due 2029, and 1.250% Senior Notes due 2031.

On what date was this 8-K report filed?

This 8-K report was filed on July 25, 2024.

What is AbbVie Inc.'s Standard Industrial Classification (SIC) code?

AbbVie Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Where is AbbVie Inc. incorporated and what is its fiscal year end?

AbbVie Inc. is incorporated in Delaware (DE) and its fiscal year ends on December 31 (1231).

From the Filing

0001551152-24-000026.txt : 20240725 0001551152-24-000026.hdr.sgml : 20240725 20240725074117 ACCESSION NUMBER: 0001551152-24-000026 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240725 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240725 DATE AS OF CHANGE: 20240725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 241139830 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20240725.htm 8-K abbv-20240725 0001551152 false 0001551152 2024-07-25 2024-07-25 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-07-25 2024-07-25 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-07-25 2024-07-25 0001551152 exch:XNYS abbv:Sec0.750SeniorNotesDue2027Member 2024-07-25 2024-07-25 0001551152 exch:XNYS abbv:Sec2.125SeniorNotesdue2028Member 2024-07-25 2024-07-25 0001551152 abbv:Sec2625SeniorNotesDue2028Member exch:XNYS 2024-07-25 2024-07-25 0001551152 abbv:Sec2125SeniorNotesDue2029Member exch:XNYS 2024-07-25 2024-07-25 0001551152 abbv:Sec1.250SeniorNotesdue2031Member exch:XNYS 2024-07-25 2024-07-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): July 25, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐                       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027 ABBV27 New York Stock Exchange 2.125% Senior Notes due 2028 ABBV28 New York Stock Exchange 2.625% Senior No

View on Read The Filing